All stock lists
Metlife Inc (MET)
NYSE: MET · Real-Time Price · USD
Financial Services · Insurance - Life
99.68+0.86 (+0.87%)
Insider Score
––Not scored
MET Insider Score
Insiders here have filed 23 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
MET analyst forecast
MET analyst consensus
Moderate Buy9 ratings
Buy 9 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
MET 12-month price target
$103.63+3.9% upsideaverage of 8 firms
$111.00High
$94.00Low
Best analysts covering MET
- Jefferies100%success rate · 6 calls
- B of A Securities100%success rate · 2 calls
- Keefe, Bruyette & Woods89%success rate · 9 calls
- Barclays80%success rate · 10 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
MET analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | TD Cowen | Buy | — | — | Reiterated | 2026-10-21 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-10-15 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-10-12 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-10-07 |
| Mizuho | Outperform | $109.00 | +12.2% | Reiterated | 2026-10-07 | |
| UBS | Buy | $110.00 | +13.5% | Reiterated | 2026-10-06 | |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-10-05 |
| Piper Sandler | Overweight | $110.00 | +13.8% | Upgraded | 2026-09-22 | |
| Morgan Stanley | Overweight | $111.00 | +15.9% | Reiterated | 2026-08-24 | |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-08-19 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-08-11 |
| — | Keefe, Bruyette & Woods | Outperform | — | — | Reiterated | 2026-08-11 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-08-06 |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-07-22 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-07-21 |
| — | Evercore ISI Group | In Line | — | — | Reiterated | 2026-07-13 |
| — | Keefe, Bruyette & Woods | Outperform | — | — | Reiterated | 2026-07-13 |
| Jefferies | Buy | $103.00 | +13.0% | Reiterated | 2026-07-10 | |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-07-09 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-07-09 |
| UBS | Buy | $105.00 | +16.3% | Reiterated | 2026-07-08 | |
| Barclays | Overweight | $94.00 | +3.9% | Reiterated | 2026-07-07 | |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-07-06 |
| — | Piper Sandler | Neutral | — | — | Reiterated | 2026-06-24 |
| — | Piper Sandler | Neutral | — | — | Reiterated | 2026-05-26 |
| Morgan Stanley | Overweight | $93.00 | +11.4% | Reiterated | 2026-05-21 | |
| — | Keefe, Bruyette & Woods | Outperform | — | — | Reiterated | 2026-05-13 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-05-12 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-05-12 |
| Mizuho Securities | — | $95.00 | +20.5% | — | 2026-05-08 | |
| Barclays | Overweight | $93.00 | +16.0% | Reiterated | 2026-05-07 | |
| — | B of A Securities | Buy | — | — | Reiterated | 2026-04-14 |
| Mizuho | Outperform | $93.00 | +24.6% | Reiterated | 2026-04-13 | |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-04-10 |
| — | UBS | Buy | — | — | Reiterated | 2026-04-09 |
| — | Evercore ISI Group | In Line | — | — | Reiterated | 2026-04-09 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-04-08 |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-03-11 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-03-03 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-02-25 |
| Evercore ISI Group | In Line | $95.00 | +21.9% | Reiterated | 2026-02-11 | |
| — | UBS | Buy | — | — | Reiterated | 2026-02-05 |
| Wells Fargo | Overweight | $97.00 | +23.9% | Reiterated | 2026-01-13 | |
| — | UBS | Buy | — | — | Reiterated | 2026-01-08 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-12-23 |
| — | Keefe, Bruyette & Woods | Outperform | — | — | Reiterated | 2025-11-11 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-11-07 |
| — | UBS | Buy | — | — | Reiterated | 2025-11-06 |
| — | B of A Securities | Buy | — | — | Reiterated | 2025-11-06 |
| — | B of A Securities | Buy | — | — | Reiterated | 2025-10-13 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-10-08 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-10-08 |
| Morgan Stanley | Overweight | $97.00 | +17.3% | Reiterated | 2025-10-07 | |
| Piper Sandler | Neutral | $84.00 | +6.2% | Downgraded | 2025-09-19 | |
| Wolfe Research | — | $95.00 | +18.1% | — | 2025-09-15 | |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-08-18 |
| — | Jefferies | Buy | — | — | Reiterated | 2025-08-11 |
| — | Keefe, Bruyette & Woods | Outperform | — | — | Reiterated | 2025-08-11 |
MET earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-04 | 2.34 | 2.58 | $27.22B | $23.81B |
| 2026-05-06 | 2.27 | 2.42 | $19.49B | $19.68B |
| 2026-08-05 | 2.30 | 2.43 | $19.67B | $19.07B |
| 2026-11-04 | 2.77 | 0.00 | $19.86B | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.